t randomization yielded an HR of 0.86 (95% CI: 0.68 to 1.1) in patients who received prior bevacizumab and an HR of 0.79 (95% CI: 0.67 to 0.93) in patients without prior bevacizumab exposure.
How Supplied/Storage and Handling
How Supplied
Zaltrap is supplied in 5 mL and 10 mL vials containing ziv-aflibercept at a concentration of 25 mg/mL.
NDC 0024-5840-01: carton containing one (1) single-use vial of 100 mg per 4mL (25 mg/mL)
NDC 0024-5840-03: carton containing three (3) single-use vials of 100 mg per 4 mL (25 mg/mL)
NDC 0024-5841-01: carton containing one (1) single-use vial of 200 mg per 8 mL (25 mg/mL)
Storage and Handling
Store Zaltrap vials in a refrigerator at 2 to 8°C (36 to 46°F). Keep the vials in the original outer carton to protect from light.
Zaltrap is a registered trademark of Regeneron Pharmaceuticals, Inc.
© 2012 Regeneron Pharmaceuticals, Inc. / sanofi-aventis U.S. LLC
PRINCIPAL DISPLAY PANEL - 100 mg/4 mL Vial Carton
NDC 0024-5840-01
Zaltrap®
(ziv-aflibercept)
Injection for
Intravenous Infusion
100 mg/4 mL
(25 mg/mL)
For intravenous infusion only.
Not to be administered by
other routes.
Hyperosmotic, must be diluted.
Single-use vial.
Discard unused portion
Rx ONLY
REGENERON
SANOFI
PRINCIPAL DISPLAY PANEL - 200 mg/8 mL Vial Carton
NDC 0024-5841-01
Zaltrap®
(ziv-aflibercept)
Injection for
Intravenous Infusion
200 mg/8 mL
(25 mg/mL)
For intravenous infusion only.
Not to be administered by
other routes.
Hyperosmotic, must be diluted.
Single-use vial.
Discard unused portion
Rx ONLY
REGENERON
SANOFI
